PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

PTC Therapeutics, Inc.NASDAQ: PTCT

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 94.5%

Gross margin was 94.5% in Q2 FY2026, up 0.9 pp from a year earlier. On a trailing-twelve-month basis it was 82.1%, down 14.9 pp year over year. Over 3 fiscal years it widened by 2.2 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
94.5%+4.8 pp QoQ
Last fiscal yearDec 2025
95.9%+3.0 pp YoY
LTMJun 2026
82.1%-14.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.9 pp——
1 year+3.0 pp——
3 years+2.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
95.9%
Year-over-year change
+3.0pp

Gross Margin vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 gross margin of 82.1% is the 6th highest of the 8 companies compared; the peer median is 93.3%.
  • Its year-over-year change of -14.9 pp is the 7th highest of 8, against a peer median of -1.6 pp.
  • Over three fiscal years its change of +2.2 pp compares with a peer median of -4.8 pp.
PTCT Competitors Peer median
Gross Margin for PTCT and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 202693.3% -2.8 pp-1.2 pp
KRYSKrystal Biotech, Inc.LTM Jun 202693.3% -0.0 pp—
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 202679.9% -1.4 pp+1.1 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 202662.4% -19.4 pp-25.1 pp
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
Peer median (excluding PTCT) 93.3%-1.6 pp-4.8 pp

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue538.59M698.8M937.82M806.78M1.73B
Cost of Revenue32.33M44.68M65.49M57.4M71.76M
Gross Profit506.27M654.12M872.34M749.38M1.66B
Gross Margin94.0%93.6%93.0%92.9%95.9%
Research & Development540.68M651.5M666.56M534.48M455.25M
Selling, General & Admin285.77M326M332.54M300.91M347.14M
Operating Expenses880.71M1.1B1.31B1.05B802.39M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
EBITDA(368.18M)(367.78M)(330.34M)(120.46M)887.66M
EBITDA Margin-68.4%-52.6%-35.2%-14.9%51.3%
Operating Income(374.44M)(447.41M)(439.5M)(302.57M)856.51M
Operating Margin-69.5%-64.0%-46.9%-37.5%49.5%
Interest Income00000
Interest Expense86.02M90.87M129.18M166.99M152.23M
Other Income / Expenses(143.9M)(140.08M)(256.61M)(60.55M)(159.89M)
Income Before Tax(518.34M)(587.49M)(696.11M)(363.12M)696.62M
Pre-Tax Margin-96.2%-84.1%-74.2%-45.0%40.3%
Income Tax Expense5.56M(28.47M)(69.51M)176K13.98M
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Net Margin-97.3%-80.0%-66.8%-45.0%39.4%
EPS (Basic)(7.43)(7.79)(8.37)(4.73)8.58
EPS (Diluted)(7.43)(7.79)(8.37)(4.73)7.78
Weighted Avg Shares70.47M71.73M74.84M76.85M79.53M
Weighted Avg Shares (Diluted)70.47M71.73M74.84M76.85M88.31M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.